Effect of nedocromil sodium on mediator release from mast cells

Bronchial asthma is a complex inflammatory disorder that involves activation of, and mediator release by, a variety of cells including mast cells. Nedocromil sodium can inhibit the activity of a range of inflammatory cells including mast cells, as has been demonstrated in several studies. In human beings nedocromil sodium inhibited histamine secretion from mast cells obtained by bronchoalveolar lavage and from dispersed lung mast cells. Tachyphylaxis was noted with the latter cells only. Because the bronchoalveolar lavage mast cells would come into direct contact with inhaled drugs, these cells may be a major target for the action of nedocromil sodium. The inhibitory effects of nedocromil sodium on mast cell activation and secretion are one way the drug may be effective in controlling airway obstruction.